Early Stage Type 1 Diabetes Initial Screen
DBS immunoassay screen for early Type 1 diabetes: detects GAD65, IA-2, ZnT8, and insulin autoantibodies; reflexes to individual autoantibody identification.
Accessed through the UncoverT1D Sponsored Testing Program•Sponsored by Sanofi•Performed by Revvity Omics, Inc.
Designed to support clinical decision-making and ordering in your practice.
For healthcare providers
Overview
Uncover T1D is a sponsored, no-cost program supporting early identification of autoimmune Type 1 diabetes via a DBS immunoassay panel for GAD65, IA-2, ZnT8, and insulin autoantibodies, with reflex to individual antibody identification when appropriate. Performed by Revvity Omics, the program is ordered at clinician discretion and may include confirmatory or follow-up testing as clinically indicated.
When to consider this test
Patient selection
- Patient has a valid Canadian Health Card/Interim Health Program card.
- Patient resides in Canada (or is currently located in Canada on a visa or similar).
- Informed consent obtained (patient or caregiver).
- Patient meets screening eligibility criteria for UncoverT1D.
- Patient does not have publicly covered access to comprehensive 4-AAb testing.
Workflow
How to use this program
- 1
Verify & order
Confirm Canadian eligibility (health card, residence, no public coverage for 4-AAb), obtain consent, and submit the UncoverT1D requisition.
- 2
Collect & ship
Collect DBS per kit instructions, label appropriately, include pertinent clinical notes, and ship per program guidelines.
- 3
Review
Interpret results, counsel, and arrange confirmatory/follow-up if needed.
Billing overview
Program billing
For eligible patients, the sponsor has arrangements with the laboratory that may reduce or cover some or all of the patient's out-of-pocket cost. Actual cost and patient responsibility vary by program criteria. Refer to lab or sponsor materials for details.
Quality & privacy
Laboratory quality & data handling
Testing is performed by Revvity Omics, Inc., a CLIA-certified laboratory (CLIA 39D0673919). Your sample is processed using validated methods and quality controls to support reliable genetic results.
Your health information is handled under privacy and security practices that are intended to align with applicable regulations. For program- and lab-specific details, review the privacy information provided by the laboratory and sponsor.
FAQ
Frequently asked questions
When should I order?
For patients meeting program screening criteria where early T1D autoantibody assessment is clinically indicated.
What does the panel include?
DBS immunoassay for GAD65, IA-2, ZnT8, and insulin autoantibodies, with reflex to individual antibody identification.
Who is eligible?
Patients residing in Canada with a valid Health Card/IHP card, informed consent, and no publicly covered access to comprehensive 4-AAb testing.
Which specimen is accepted?
DBS per kit instructions; include requisition, consent, and pertinent clinical notes.
Turnaround time?
Not specified by the program; set expectations locally based on current lab operations.
Are confirmatory and follow-up tests included?
Yes—both are available within the program when clinically indicated and remain no-cost to the patient.
Is this for carrier testing?
No. This program is not intended for carrier testing.
See an issue with this program?